Dr. Aguiar has been a member of our Board of Directors since September 2010. He has been a partner at Aisling Capital, an investment firm specializing in products, technologies, and global businesses that advance health since January 2016. Prior to Aisling Capital, from October 2007 to December 2015, he was a partner at Thomas, McNerney & Partners, a healthcare venture capital and growth equity firm. From 2001 to 2007, Dr. Aguiar was a managing director of HealthCare Ventures, a healthcare focused venture capital firm. He was chief executive officer and a director of Genovo, Inc., a biopharmaceutical company focused on gene delivery and gene regulation, from 1998 to 2000. Since December 2020, he has served as a director of Biomea Fusion, Inc., a preclinical-stage biopharmaceutical company. Additionally, he has served as a director of BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company since 2019. Dr. Aguiar previously served as a director of Eidos Therapeutics, Inc. in addition to Biohaven Pharmaceutical Holding Company Ltd. and Amarin Pharmaceuticals, each a public biopharmaceutical company, as well as on the boards of directors of numerous private companies including companies in the life sciences industry. Since September 2021, Dr. Aguiar has served as a director of Garuda Therapeutics, a company focused on developing blood stem cell therapies. He is also a member of the Council on Foreign Relations. Dr. Aguiar received an M.D. with honors from Harvard Medical School and a B.A. in Arts and Sciences from Cornell University. Dr. Aguiar was also a Luce Fellow and is a Chartered Financial Analyst. We believe that Dr. Aguiar is qualified to serve on our Board of Directors due to his extensive experience with life sciences companies.

Mr. Crouse has served on our Board of Directors since March 2012. Mr. Crouse has served as chief executive officer of Candela Corporation, a non-surgical aesthetic device company since July 2017. From December 2015 to July 2017, Mr. Crouse was a consultant for private equity evaluating investment opportunities. Mr. Crouse served as chief executive officer of Cord Blood Registry, a company that stores stem cells from umbilical blood and tissues, from September 2012 to August 2015 when it was sold to AMAG Pharmaceuticals, and served as executive vice president of AMAG until December 2015. From April 2011 through September 2012, Mr. Crouse was a consultant for private equity evaluating investment opportunities. He previously served as chief operating officer at Immucor, Inc., an in vitro diagnostics company, from August 2009 to April 2011. Prior to Immucor, he served as vice president of the life sciences business at Millipore Corporation, a provider of technologies, tools and services for the life sciences industry, from 2006 to 2009. Prior to that, he worked at Roche, a pharmaceuticals and diagnostics company, where he held various roles from 2003 to 2006. Mr. Crouse holds a B.A. in English and Japanese from Boston College and an MBA and Masters of Public Health from the University of California, Berkeley. We believe that Mr. Crouse is qualified to serve on our Board of Directors due to his extensive experience in the life sciences industry and his management and financial experience with life sciences companies.

Ms. Gorjanc has served on our Board of Directors since November 2015. She is an experienced financial executive with expertise gained through service as a chief financial officer as well as working in multinational public companies. Ms. Gorjanc served as the chief financial officer of Arlo Technologies, Inc., a home automation company, from August 2018 to June 2020. She previously served as the chief financial officer of Netgear, Inc., a provider of networking products and services, from January 2008 to August 2018, where she also served as chief accounting officer from December 2006 to January 2008 and vice president for finance from November 2005 to December 2006. From September 1996 through November 2005, Ms. Gorjanc served as vice president, controller, treasurer and assistant secretary for Aspect Communications Corporation, a provider of workforce and customer management solutions. From October 1988 through September 1996, she served as the manager of tax for Tandem Computers, Inc., a provider of fault-tolerant computer systems. Prior to that, Ms. Gorjanc served in management positions at Xidex Corporation, a manufacturer of storage devices, and spent eight years in public accounting with a number of public accounting firms. Ms. Gorjanc joined the board of Shapeways Holdings, Inc., a leader in the fast-growing digital manufacturing industry, in March 2023. Since May 2019, Ms. Gorjanc has served as a director of Juniper Networks, Inc., a leader in secure AI driven networks, and from March 2021 to October 2022, Ms. Gorjanc served as a director of Zymergen Inc., a biotechnology company. Ms. Gorjanc holds a B.A. in accounting from the University of Texas at El Paso and an M.S. in taxation from Golden Gate University. In April 2022, Ms. Gorjanc achieved NACD Directorship Certified status (National Association of Corporate Directors). We believe that Ms. Gorjanc is qualified to serve on our Board of Directors due to her extensive experience in the technology industry and her management and financial experience.

Ms. Lockhart has been an Invitae Board member since 2020. She currently serves on the boards of private and public companies, including as a director of Beam Technologies Inc., a digital-first provider of employee benefits for businesses, since July 2019. Previously, Ms. Lockhart served in various capacities at 1Life Healthcare, Inc., dba One Medical, a membership-based primary care platform, including as advisor from July 2021 to December 2021, chief technology officer from March 2015 to June 2021, and vice president of engineering from April 2014 to March 2015. Ms. Lockhart holds a B.S. in Computer Science from Stanford University. We believe that Ms. Lockhart is an experienced technology leader and has scaled technology platforms to support rapid business growth and is therefore qualified to serve on our Board of Directors.

Ms. Nayak serves as the environmental, social and governance (ESG) lead of our Board of Directors and is a public and private company board director for several businesses and an advisor to technology startups and venture firms – 1414 Ventures and Plum Alley. From January 2019 to May 2021, she served as an adjunct faculty member at California State University’s MBA program. Ms. Nayak served as the chief operating officer of Comfy, Inc., a real-estate technology company in the machine learning and IoT space, from February 2017 to June 2018, when it was acquired by Siemens. Prior to that role, Ms. Nayak was the chief operating officer of Funding Circle Ltd., an online peer-to-peer lending marketplace, from February 2015 to May 2016. Prior to joining Funding Circle, Ms. Nayak worked at Salesforce, Inc., a cloud computing company, for eight years, serving in a variety of roles including chief operating officer of platform from February 2013 to January 2015, senior vice president of global sales development from February 2008 to January 2013 and vice president of marketing strategy and operations from February 2007 to January 2008. From 2004 to 2006, she served as vice president, membership products for California State Automobile Association, a provider of automobile insurance. From 1999 to 2003, Ms. Nayak served as vice president of strategy and operations of Charles Schwab Corporation, an investment and brokerage firm. Prior to that, Ms. Nayak spent six years with the Boston Consulting Group and four years with a number of environmental engineering consulting firms. Since March 2021, Ms. Nayak has served as a director of Infosys Limited, an information technology company, and as a director of Forward Air Corporation. From November 2020 until its acquisition by TELUS Corporation in September 2022, she served as a director of LifeWorks Inc.. Ms. Nayak has served on the boards of directors of Intercom, a messaging platform company, since January 2020, and UrbanFootprint, a social impact data platform company, since March 2021. Ms. Nayak holds a B.S. in Engineering from the Indian Institute of Technology, an M.S. in Environmental Engineering from Cornell University, and an MBA from Harvard Business School (with honors). We believe that Ms. Nayak is qualified to serve on our Board of Directors due to her substantial experience scaling companies through high-growth phases as well as her background in operations and go-to-market strategies for complex businesses.

Mr. Osborne has been a member of our Board of Directors since January 2023 and serves on the Audit Committee. He most recently served as senior vice president of operations and total quality for Boeing Defense, Space & Security (BDS) at The Boeing Company, an aerospace company, from May 2020 to October 2022, and as Boeing’s senior vice president of Eenterprise operations, from May 2018 until April 2020. Prior to that, Mr. Osborne served in various capacities at Navistar, Inc., a producer of commercial and military trucks, including as senior vice president of global manufacturing and quality from August 2013 to August 2018, as senior vice president of custom products from May 2011 to August 2013, and as corporate director from September 2009 to April 2012. Prior to his time at Navistar, from September 2008 to October 2010, Mr. Osborne served as president and chief executive officer of Federal Signal Corporation, a manufacturer of emergency vehicle equipment. Mr. Osborne has served on the board of directors at Quaker Chemical Corporation, a chemical company, since December 2016. Mr. Osborne also serves on the board of directors of Armstrong World Industries, Inc., a designer and manufacturer of walls and ceilings, since July 2022. Mr. Osborne holds a B.S. in Mechanical Engineering from Kettering University, an M.S. in Engineering from Wayne State University, and an MBA from University of Chicago. We believe that Mr. Osborne is qualified to serve on our Board of Directors due to his considerable track record of operational leadership.